Small Molecule TNF-alpha Inhibitor for the Treatment of Arthritis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$249,927.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43AR056917-01
Award Id:
93477
Agency Tracking Number:
AR056917
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NOVELMED THERAPEUTICS, INC., 2265 ENTERPRISE PKWY, TWINSBURG, OH, 44087
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
190155171
Principal Investigator:
REKHA BANSAL
(440) 477-9874
REKHA@NOVELMED.COM
Business Contact:
REKHA BANSAL
() -
rekha@novelmed.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with joint inflammation, destruction, deformities, and increased mortality rates that affect 1.3 million Americans. Current approaches for treating RA are inadequate in preventing the devastating inflammation and joint destruction that result from RA. Current therapies target tumor necrosis factor alpha (TNF-1). Remicade is an anti-TNF-1 antibody and Enbrel is a sTNF-1 receptor. Both drugs are very ex pensive and given intravenously, and do not cure the disease. These drugs do not prevent the production of excessive TNF-1 and thus can only halt the progression of the disease when given to patients. If patients stop taking the drug, their condition deter iorates. Due to the cost of these drugs, only a high income group can gain access to treatment. NovelMed has identified, through small molecule screening, a potent inhibitor of TNF-1 production, which we designated as NM2014. The molecule inhibits inflamma tion and joint damage in a rat model of adjuvant-induced arthritis. We propose to evaluate its efficacy in rat AIA and mouse collagen-induced arthritis models of RA. In phase II, we would like to file an Investigational New Drug (IND) application for a saf ety and efficacy clinical trial. NovelMed's lead drug candidate is a highly promising, orally viable small molecule, which has already received an FDA approval in the US for other clinical indications. NovelMed has filed a patent application on this novel molecule for the treatment of arthritis. If successful, it could become a multi-billion dollar drug. Public Health Relevance: Annually billions of dollars is spent for arthritic patients. Current treatments are expensive and can only halt the progression o f the disease. No treatment currently exists that is inexpensive and provides long-term benefit to RA patients. NovelMed has discovered an inexpensive treatment for arthritis patients and once approved by the FDA for arthritis, it would be available to the large population, which is anxiously waiting for an affordable treatment.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government